• Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

    Source: Nasdaq GlobeNewswire / 29 Jan 2025 16:15:00   America/New_York

    PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:

    Guggenheim SMID Cap Biotech Conference
    Date: Thursday, February 6, 2025
    Time: 1pm ET / 7pm CET
    Location: New York, NY
    Presenter: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
    Webcast link: Click here

    Leerink Global Healthcare Conference
    Date: Wednesday, March 12, 2025
    Time: 10:40pm ET / 4:40pm CET
    Location: Miami, FL
    Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
    Webcast link: Click here

    The fireside chats will be webcast live from the events page of the Investors section of the Company’s website. Replay of the webcast will be available following the event.

    About NANOBIOTIX

    Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

    Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

    Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

    For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

    Contacts

    Nanobiotix 
    Communications Department
    Brandon Owens
    VP, Communications
    +1 (617) 852-4835
    contact@nanobiotix.com    		Investor Relations Department
    Craig West
    SVP, Investor Relations
    +1 (617) 583-0211
    investors@nanobiotix.com    		 
      
    Media Relations 


    France – HARDY
    Caroline Hardy
    +33 06 70 33 49 50
    carolinehardy@outlook.fr

          		Global – LifeSci Advisors
    Kevin Gardner
    +1 (617) 283-2856
    kgardner@lifesciadvisors.com    		 

     

    Attachments


Share on,